Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Fineline Cube Feb 25, 2026
Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026
Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026
Company Deals Digital

Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis

Fineline Cube Feb 25, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

Fineline Cube Feb 25, 2026
Company Drug

Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month

Fineline Cube Feb 25, 2026
Company Deals

Danaher Corporation to Establish Northern China Headquarters in Beijing’s Changping District

Fineline Cube Jan 19, 2024

The Changping District People’s Government of Beijing Municipality has entered into a strategic cooperation agreement...

Company Deals

Glorious Med and Illumina Join Forces for Advanced Urinary Tract Infection Detection

Fineline Cube Jan 19, 2024

Hangzhou-based Glorious Med, a premier company specializing in gene detection for urinary system tumors, has...

Company Drug

CARsgen Therapeutics’ CT041 Shows Promising Results in Advanced Solid Tumors at ASCO GI 2024

Fineline Cube Jan 19, 2024

China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the presentation of...

Company Medical Device

Ultrasound Biotechnology Earns FDA Nod for Disposable Endoscopic Ultrasound Probes

Fineline Cube Jan 19, 2024

Ultrasound Biotechnology, the Shanghai-based wholly owned subsidiary of US firm Ultrasound Wondering, Inc., has announced...

Company Deals Digital

Meinian Onehealth Collaborates with Huawei Cloud and Runda Medical on AI Health Robot

Fineline Cube Jan 19, 2024

Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a strategic partnership with...

Company Deals

Sinovac Biotech Ltd Dismisses UK Private Equity’s Nominal Share Acquisition Offer

Fineline Cube Jan 19, 2024

Sinovac Biotech Ltd (NASDAQ: SVA) has released a statement declaring that its board of directors...

Company Drug

Beijing Aosaikang Initiates Phase III Trial for Advanced Gastric Cancer Treatment

Fineline Cube Jan 18, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase...

Company Deals R&D

Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion

Fineline Cube Jan 18, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a...

Company Drug

FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia

Fineline Cube Jan 18, 2024

Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...

R&D

Sun Yat-sen University Researchers Develop AI Model for Early Ovarian Cancer Detection

Fineline Cube Jan 18, 2024

Researchers at Guangzhou’s Sun Yat-sen University Cancer Center have made a significant breakthrough with the...

Company Drug

Shanghai-Based NK CellTech Earns FDA IND Clearance for Non-Genetically Modified NK Cell Therapy

Fineline Cube Jan 18, 2024

NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received...

Policy / Regulatory

Hainan Province Unveils Measures to Support Innovative Drugs and Medical Devices Development

Fineline Cube Jan 18, 2024

Hainan provincial bureaus, including the Healthcare Security Administration (HSA), Healthcare Commission, and Medical Products Administration,...

Legal / IP Policy / Regulatory

Shanghai Medical Products Administration Issues Trial Measures for Pharmaceutical Quality and Safety Personnel

Fineline Cube Jan 18, 2024

The Shanghai medical products administration has released the “Measures for the Management of Key Quality...

Company Legal / IP

USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo

Fineline Cube Jan 18, 2024

In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...

Company

Bayer Unveils New Operating Model to Drive Profitable Growth Amid Challenges

Fineline Cube Jan 18, 2024

Facing a challenging business landscape, Germany’s Bayer (ETR: BAYN) has announced a new operating model...

Company Drug

Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results

Fineline Cube Jan 18, 2024

Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...

Legal / IP Policy / Regulatory

Shanghai Enhances Biomedicine IP Protection with New Procurement-Linked Measures

Fineline Cube Jan 18, 2024

The Shanghai Intellectual Property Administration (SIPA) has issued a notification highlighting the city’s intensified efforts...

Company Drug

Hansoh Pharmaceutical Advances Schizophrenia Treatment with HS-10509 Clinical Trial Approval

Fineline Cube Jan 18, 2024

Hansoh Pharmaceutical (HKG: 3692) has announced that it has received approval to commence clinical trials...

Company Drug

Sino Biopharmaceutical Receives NMPA Approval for Generic Revolade Equivalent

Fineline Cube Jan 18, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a major player in the Chinese pharmaceutical industry, announced that...

Company Drug

Luye Pharma’s Biosimilar Bevacizumab Gets GMP Certification in Brazil

Fineline Cube Jan 18, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...

Posts pagination

1 … 373 374 375 … 626

Recent updates

  • Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD
  • MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks
  • Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor
  • AbbVie Invests $380M in Illinois API Manufacturing – AI‑Enabled Facilities for Neuroscience and Obesity Drugs
  • Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Company

AbbVie Invests $380M in Illinois API Manufacturing – AI‑Enabled Facilities for Neuroscience and Obesity Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.